Autolus Therapeutics PLC (NAS:AUTL)
$ 3.92 0.05 (1.29%) Market Cap: 1.04 Bil Enterprise Value: 335.67 Mil PE Ratio: 0 PB Ratio: 1.79 GF Score: 55/100

Autolus Therapeutics PLC at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 11:00PM GMT
Release Date Price: $2.87 (+0.70%)
Rajan Sharma
Goldman Sachs Group, Inc., Research Division - Research Analyst

All right. Good afternoon, everyone. My name is Rajan Sharma. I'm one of the European biotech analyst here at Goldman Sachs. I'm pleased to have Christian Itin, who's the CEO at Autolus, join us for a fireside this afternoon. Christian, thank you for taking the time. Maybe you want to kind of start by giving a high-level overview of Autolus and kind of the technology platforms that you have.

Christian Martin Itin
Autolus Therapeutics plc - CEO & Director

Yes, happy to do that. First of all, thanks for the invitation. Always great to come out of California and get a bit of (inaudible), although the June gloom certainly had its moments this morning. I'm Christian Itin, CEO of Autolus. We had a very exciting last few months actually behind us. We're just coming off ASCO, where we had shown pivotal data for our LEAP program called Obe-cel that we developed in patients with acute lymphoblastic leukemia, had very nice data, very good safety profile, high level of activity. And as you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot